Why DBV Technologies Stock Popped Today
After hitting a major regulatory roadblock, DBV Technologies sees a path to approval for its leading candidate.
DBV Technologies S.A.
After hitting a major regulatory roadblock, DBV Technologies sees a path to approval for its leading candidate.
The company submitted its potential peanut allergy treatment for review in Europe.
Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.
The FDA rejected the company’s application for its peanut-allergy patch.
The company provided a grim business update.
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
A sizable capital raise sent shareholders running for the exits this morning.
Long-term data suggests longer treatments with Viaskin Peanut improve peanut tolerance.
Traders cheered after the company announced the pricing details of a stock offering.
Find out why these stocks stood out on a down day for the market.